DESTINY-Breast03 Phase 3 Study Results
Datopotamab deruxtecan + durvalumab as first-line treatment for
unresectable locally advanced/metastatic triple-negative breast
cancer
Initial results from BEGONIA, a phase 1b/2 study
Peter Schmid, FRCP, MD, PhD
Barts Cancer Institute, Queen Mary University of London, London, UK
K. H. Jung, P. J. Wysocki, 2 J. Jassem, ³ C. X. Ma, 4 R. Fernandes, 5 R. Huisden, 6 R. Stewart, 6 P. Vukovic, 6
A. Tablante Nunes, 7 Z. Nowecki8
1Asan Medical Center - University of Ulsan, College of Medicine, Seoul, Korea; 2Jagiellonian University - Medical College, Krakow, Poland;
3 Medical University of Gdańsk, Gdańsk, Poland; 4Washington University School of Medicine, St. Louis, MO, USA; 5Schulich School of
Medicine & Dentistry, Western University, London Health Sciences Centre, London, Canada; 6AstraZeneca, Cambridge, UK; AstraZeneca,
Gaithersburg, MD, USA; ³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
ESMO BC 2022 #166 Mini Oral
On behalf of the investigators
Daiichi-Sankyo
22
72View entire presentation